Overview
At GeneVantage, we are pioneering a new class of gene therapies designed to target and treat rare genetic disorders that currently lack effective treatments. Our approach utilizes cutting-edge CRISPR technology to edit genes at the source, providing potentially life-saving interventions. Since our inception, we have successfully completed initial preclinical trials with promising results, demonstrating the feasibility and effectiveness of our therapies. Our team consists of experienced biotechnologists and medical professionals with a proven track record in genetic research and development. We are now at a crucial juncture where we need to scale our operations. Investment will allow us to fund our upcoming clinical trial phases and expand our laboratory facilities to accelerate the development process. The global market for gene therapy is projected to reach $50 billion by 2027, and with fewer than 1% of rare disorders currently having a viable treatment, our solutions are positioned to meet a significant and urgent need. We’ve already engaged with key stakeholders in the biotech industry and have received interest from potential partners in the pharmaceutical sector, validating ou…
Use of funds
The requested investment of $710,000 will be allocated as follows:
- R&D Development: $350,000 for enhancing laboratory capabilities and expanding our research team.
- Clinical Trials: $250,000 to fund the next phase of clinical trials, including patient recruitment and regulatory compliance.
- Marketing & Outreach: $50,000 for building awareness and relationships with potential clients and partners.
- Operational Costs: $60,000 to cover administrative expenses and operational overheads as we scale.
Open case
Open this case to get the detailed business plan and direct contact with the founder or seeker.